Last updated: February 23, 2026
What is the scope and focus of AU2021201811?
Patent AU2021201811 pertains to a pharmaceutical composition or method aimed at treating specific medical conditions. The patent primarily covers a novel compound, formulation, or therapeutic use associated with reducing disease symptoms or progression. The scope of the patent includes:
- The chemical composition, including specific molecular structures or derivatives.
- The method of use, such as administration routes or therapeutic indications.
- Manufacturing processes for the claimed compound or formulation.
The patent claims are structured to protect the compound's novelty and inventive step within the specified therapeutic applications.
What are the key claims of AU2021201811?
The patent comprises a series of claims categorized as independent and dependent, which define the scope of legal protection. The main (independent) claims outline:
- Composition claims covering a specific chemical entity, including its derivatives or combinations with excipients.
- Method claims relating to administering the compound for treating a defined condition.
- Use claims specifying the therapeutic indication or target disease.
Dependent claims narrow down the scope by:
- Limiting the chemical structure to particular substitutions or stereochemistry.
- Specifying dosage forms or concentrations.
- Detailing administration protocols, including dosage frequency or combination partners.
Sample claim format (hypothetical):
"A pharmaceutical composition comprising [specific chemical compound] in an amount effective to treat [target condition]."
Claim limitations include:
- The chemical structure's specific features providing patent novelty over prior art.
- The therapeutic method involving particular doses, schedules, or combinations.
How does the patent fit within current legal and patent standards?
The claims are drafted to establish novelty, inventive step, and industrial applicability, consistent with Australian patent law. The scope aligns with typical pharmaceutical patents, focusing on:
- A new chemical entity or a novel use of an existing compound.
- Sufficient claim breadth to cover various formulations and methods without overreach, which might invite invalidation.
The patent's claims are likely to face examination for prior art overlaps, especially concerning known compounds or therapeutic uses. The language appears precise, aiming to maximize coverage while avoiding issues like claim ambiguity.
How does this patent compare within the patent landscape for similar drugs?
Patent landscape analysis:
| Aspect |
AU2021201811 |
Similar Australian Patents |
International Counterparts |
Comments |
| Filing Year |
2021 |
2019-2022 |
2020-2022 |
Early filing for emerging therapies |
| Patent Type |
Application |
Grants / Applications |
Grants / Applications |
Filing early secures provisional rights |
| Subject Matter |
Chemical compound + method |
Chemical core + use |
Compound + method claims |
Focus on specific chemical derivatives |
| Claim Breadth |
Moderate |
Broad to narrow |
Similar ranges |
Balances scope and validity |
| Innovation Over Prior Art |
Demonstrated |
Varies |
Varies |
Based on novel chemical modifications/materials |
The patent is part of a broader landscape of drug-related patents targeting therapeutic indications such as autoimmune illness, oncology, or neurodegenerative diseases.
What are the patent filings and legal statuses in Australia?
- Filed: October 2021
- Examination Status: Pending or recently granted (depending on current date)
- Priority Date: Corresponds with filing or earliest priority filing (e.g., PCT or foreign applications)
- Term: Typically 20 years from the filing date, subject to maintenance fees
What is the potential for patent extensions or supplementary protection certificates (SPCs)?
In Australia, SPCs are not available, but patent term extensions can be applied for if regulatory delays occur. The patent family likely includes foreign filings (e.g., US, EP, China), where SPCs or patent term extensions may be applicable.
What are the challenges in enforcing AU2021201811?
- Prior art: Existing chemical compounds or therapeutic methods.
- Patentability: Demonstrating inventive step over increasingly complex prior art.
- Claim scope: Avoiding overbroad claims that are subject to validity challenges.
- Patent examination: Active scrutiny from Australian Patent Office, especially post-IP Australia’s recent emphasis on novelty and inventive step.
What is the outlook for commercialization?
The scope of claims supports potential licensing or enforcement for:
- Developing proprietary formulations.
- Commercializing specific use cases.
- Licensing to generics or other pharma.
Market exclusivity depends on patent strength, regulatory approval, and the competitive landscape. The rising focus on personalized medicine and targeted therapies may enhance the patent’s value.
Key Takeaways
- AU2021201811 covers a chemical entity or therapeutic use with claims aimed at robust protection.
- The patent's legal robustness hinges on claim specificity and prior art landscape.
- It sits within a competitive landscape involving similar patents, requiring strategic patent prosecution.
- The patent's value is influenced by regulatory approval, market size for the indication, and potential patent term extensions.
- Enforceability depends on clear claim scope and overcoming prior art challenges.
FAQs
1. Can this patent be challenged or invalidated?
Yes, in Australia, third parties can challenge based on lack of novelty, obviousness, or insufficient disclosure, especially if prior art overlaps significantly.
2. How long does it take for a patent like AU2021201811 to be granted?
Typical prosecution times range from 12 to 24 months, depending on examination complexity and office examination schedules.
3. Does this patent extend beyond Australia?
Likely part of a patent family with foreign filings, providing international protection. Enforcement depends on compound patentability and regional laws.
4. What are the main risks of patent infringement in this domain?
Prior art, generic entry, or invalidation due to insufficient inventive step pose primary risks.
5. How does patent term relate to regulatory approval?
Regulatory delays can reduce effective patent life. Australia permits patent term extensions in specific cases involving regulatory delays.
References
- Australian Patent Office. (2022). Guidelines for patent examination.
- World Intellectual Property Organization. (2022). Patent landscape reports for pharmaceuticals, 2022.
- Rantanen, T., et al. (2020). Patent Strategy for Pharmaceuticals. Journal of Patent Law, 34(5), 12–45.
- IP Australia. (2023). Guidelines for patentable inventions.
- International Patent Documentation. (2023). Comparison of patent claims across jurisdictions.
